Please use this identifier to cite or link to this item:
Title: White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease
Author: Sánchez del Valle Díaz, Raquel
Monté, Gemma C.
Sala Llonch, Roser
Bosch, Beatriz
Fortea, Juan
Lladó Plarrumaní, Albert
Antonell, Anna
Balasa, Mircea
Bargalló Alabart, Núria​
Molinuevo, José L.
Keywords: Malaltia d'Alzheimer
Imatges per ressonància magnètica
Diagnòstic per la imatge
Alzheimer's disease
Magnetic resonance imaging
Diagnostic imaging
Issue Date: 30-Mar-2016
Publisher: IOS Press
Abstract: PSEN1 mutations are the most frequent cause of autosomal dominant Alzheimer's disease (ADAD), and show nearly full penetrance. There is presently increasing interest in the study of biomarkers that track disease progression in order to test therapeutic interventions in ADAD. We used white mater (WM) volumetric characteristics and diffusion tensor imaging (DTI) metrics to investigate correlations with the normalized time to expected symptoms onset (relative age ratio) and group differences in a cohort of 36 subjects from PSEN1 ADAD families: 22 mutation carriers, 10 symptomatic (SMC) and 12 asymptomatic (AMC), and 14 non-carriers (NC). Subjects underwent a 3T MRI. WM morphometric data and DTI metrics were analyzed. We found that PSEN1 MC showed significant negative correlation between fractional anisotropy (FA) and the relative age ratio in the genus and body of corpus callosum and corona radiate (p <  0.05 Family-wise error correction (FWE) at cluster level) and positive correlation with mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RD) in the splenium of corpus callosum. SMC presented WM volume loss, reduced FA and increased MD, AxD, and RD in the anterior and posterior corona radiate, corpus callosum (p <  0.05 FWE) compared with NC. No significant differences were observed between AMC and NC in WM volume or DTI measures. These findings suggest that the integrity of the WM deteriorates linearly in PSEN1 ADAD from the early phases of the disease; thus DTI metrics might be useful to monitor the disease progression. However, the lack of significant alterations at the preclinical stages suggests that these indexes might not be good candidates for early markers of the disease.
Note: Reproducció del document publicat a:
It is part of: Journal of Alzheimer's Disease, 2016, vol. 51, num. 3, p. 827-835
Related resource:
ISSN: 1387-2877
Appears in Collections:Articles publicats en revistes (Biomedicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
668222.pdf319.35 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.